glp-1 induced gastroparesis receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 attenuates intestinal fat absorption
Description
Triple agonists targeting GLP-1, GIP, and glucagon receptors are in development, with early data suggesting even greater metabolic benefits
I love it
CBT is also relevant for ARFID, which can be associated or overlap with GNDs [126]
GLP-2 acts through GLP-2R, a highly specific GPCR located in the gastrointestinal tract, pancreas, and central nervous system (6063)
We find that patients benefit from at least a 12 month comprehensive weight-loss program to establish the proper habits to sustain long-term weight loss What if I'm ineligible for a GLP-1 agonist
